Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 6:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 359 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: bupropion (Zyban) Clear all
Completed Phase 3 Interventional

Pharmacological and Behavioral Treatment After Bariatric Surgery

NCT05157698
View directory record Official record
Conditions
Obesity
Interventions
Naltrexone and Bupropion Combination, Behavioral Weight Loss, Placebo
Drug · Behavioral · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation

NCT05557409
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation
Interventions
AXS-05, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
65 Years to 90 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
53
States / cities
Peoria, Arizona • Tempe, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cocaine Abuse and Attention Deficit Disorder - 3

NCT00000268
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Bupropion
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 15, 2026, 6:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pharmacogenetics of Bupropion Metabolism

NCT00791869
View directory record Official record
Conditions
Metabolism, Pharmacokinetics
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

Adaptive Pharmacotherapy for Smoking Cessation

NCT02501265
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Varenicline Standard Protocol, Nicotine Patch Standard Protocol, Varenicline Adaptive Protocol, Nicotine Adaptive Protocol
Behavioral · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 15, 2026, 6:54 AM EDT
Terminated Phase 4 Interventional

Pilot Study of Bupropion for Smoking Cessation in Postpartum Non-breastfeeding Women

NCT00119210
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Bupropion SR, placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2011 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Bupropion SR for Treating Smokeless Tobacco Use

NCT00414180
View directory record Official record
Conditions
Smokeless Tobacco
Interventions
Bupropion SR
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 15, 2026, 6:54 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

High Dose Bupropion for Smoking Cessation - Pilot Study

NCT03326128
View directory record Official record
Conditions
Smoking Cessation, Smoking, Tobacco, Smoking (Tobacco) Addiction, Cessation, Tobacco, Cigarette Smoking
Interventions
Bupropion Hydrochloride
Drug
Lead sponsor
University of Southern California
Other
Eligibility
21 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 15, 2026, 6:54 AM EDT
Terminated Phase 4 Interventional Results available

Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression

NCT00429169
View directory record Official record
Conditions
Depression
Interventions
Paroxetine, Bupropion
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Phase 4 Interventional Results available

Bupropion and Weight Control for Smoking Cessation - 1

NCT00006170
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Bupropion, Placebo, weight concerns intervention, smoking cessation intervention
Drug · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Naltrexone-Bupropion-Methamphetamine Interaction Study

NCT01359930
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
placebo, Naltrexone and Bupropion SR
Other · Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Maintenance Treatment for Abstinent Smokers

NCT00063323
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Bupropion
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 75 Years
Enrollment
589 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Phase 1Phase 2 Interventional

Phase 1b/2a Unblinded Study of Responses in Premenopausal Women With HSDD to Lorexys Evaluating Efficacy and Safety

NCT01857596
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder (DSM-IV-TR Defined), Sexual Interest/Arousal Disorder (DSM-5 Defined)
Interventions
bupropion, Lorexys low-dose, Lorexys moderate-dose
Drug
Lead sponsor
S1 Biopharma, Inc.
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Beachwood, Ohio • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

CYP2B6 Genetics and Drug Interactions in Healthy Volunteers

NCT02401256
View directory record Official record
Conditions
Healthy
Interventions
Efavirenz, Bupropion, Rosuvastatin, Montelukast
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 49 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effectiveness of Bupropion for Smokers Recovering From Alcohol Dependence

NCT00304707
View directory record Official record
Conditions
Smoking Cessation, Alcohol-Related Disorders
Interventions
Bupropion, placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 70 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Bedford, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

NCT03864042
View directory record Official record
Conditions
Advanced Solid Tumors, Metastatic Melanoma
Interventions
losartan, dextromethorphan, caffeine, omeprazole, midazolam, rosuvastatin, bupropion immediate release (IR), encorafenib, binimetinib, modafinil
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
11
States / cities
Orange, California • Aurora, Colorado • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

Assessing Symptomatic Clinical Episodes in Depression

NCT03595579
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
AXS-05, Bupropion
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Beverly Hills, California • Jacksonville, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2021 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Bupropion SR Plus Counseling for Smoking Cessation

NCT01621009
View directory record Official record
Conditions
Tobacco Dependence, Smoking
Interventions
Active bupropion + counseling, Active bupropion, No counseling, Placebo medication + counseling, Placebo medication, No counseling
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
463 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2003
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 27, 2016 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Not applicable Interventional

Smoking Relapse-Prevention Intervention for Cancer Patients

NCT01630161
View directory record Official record
Conditions
Smoking Cessation
Interventions
Usual Care, Smoking Relapse Prevention for Cancer Patients (SRP-CaP)
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

Bupropion in Helping Adults Stop Smoking

NCT00534001
View directory record Official record
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
bupropion hydrochloride, placebo
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 15, 2026, 6:54 AM EDT
Terminated Phase 4 Interventional Results available

Bupropion for Depression in ESRD Patients on Hemodialysis

NCT02238977
View directory record Official record
Conditions
Major Depression, End Stage Renal Disease
Interventions
Fluoxetine, Bupropion
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
30 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NCT03180294
View directory record Official record
Conditions
Breast Carcinoma, Cervical Carcinoma, Ovarian Carcinoma, Postmenopausal, Uterine Corpus Cancer, Vaginal Carcinoma, Vulvar Carcinoma
Interventions
Bupropion 150 mg XL, Placebo
Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
362
States / cities
Anaheim, California • Antioch, California • Baldwin Park, California + 262 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Not applicable Interventional Results available

Smoking Treatment and Exercise Program for Underserved Populations (STEP UP)

NCT02873754
View directory record Official record
Conditions
Smoking
Interventions
Cognitive Behavioral Counseling, Mobile Contingency Management, Bupropion, Transdermal nicotine patch, Nicotine polacrilex, Nicotine lozenge
Behavioral · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Phase 2 Interventional

Pharmacologic Relapse Prevention for Alcoholic Smokers

NCT00000457
View directory record Official record
Conditions
Alcoholism, Smoking
Interventions
bupropion (Wellbutrin), Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 21, 2013 · Synced Oct 15, 2026, 6:54 AM EDT